Michael Gutch - 18 Jan 2022 Form 4 Insider Report for Entasis Therapeutics Holdings Inc. (ETTX)

Role
Chief Financial Officer and Chief Business Officer
Signature
Michael Gutch
Issuer symbol
ETTX
Transactions as of
18 Jan 2022
Transactions value $
$0
Form type
4
Filing time
19 Jan 2022, 15:05:33 UTC
Previous filing
03 Nov 2021
Next filing
28 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETTX Common Stock Award $0 +125,000 +294% $0 167,572 18 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award vests over four years with twenty-five percent of the award vesting on each anniversary of the date of grant, subject to the reporting person's continued employment with the Company.

Remarks:

Chief Financial Officer and Chief Business Officer